All In Biotech

Drug Trial Radar · NCT00486343

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

A Randomized, Double-Blind, Placebo Controlled Study of Zileuton CR Tablets Versus Placebo in Adult Patients With Poorly Controlled Asthma Patients on Moderate Dose Inhaled Corticosteroids (ICS)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 2007

Primary completion

May 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Critical TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asthma is a chronic inflammatory disorder of the airways with a variety of inflammatory processes contributing to the pathogenesis. The inflammation leads to a state of increased airway responsiveness and reversible airway obstruction that causes the recurrent symptoms of asthma. Despite the variety of treatments available for asthma, none are curative, and the disease continues to place a burden on society in terms of morbidity, reduced quality of life (QOL), and ever increasing healthcare costs. The prevalence of asthma continues to increase with current data suggesting that since 1980, adult asthma cases have increased by 75% and in children under 5 years of age the prevalence has increased by 160%.1 Additionally, studies have suggested that the disease severity has been underestimated and that more patients may be classified as having moderate to severe persistent disease.2 Inhaled corticosteroids (ICS) have been the cornerstone of anti-inflammatory treatment for decades and have been shown to improve lung function, decrease symptoms, and reduce asthma exacerbations.3 However, many patients are still inadequately controlled despite treatment according to current asthma management guidelines and have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.4 Combining long-acting β2-agonists (LABAs) with low dose ICS has been shown to improve asthma control over using higher doses of ICS alone. However, LABAs act mainly at the bottom of the inflammatory cascade and there are concerns that they may mask underlying inflammation.5 Recently, leukotriene receptor antagonists have been added to ICS as second-line therapy in the management of asthma. Zileuton has been extensively studied in inflammatory diseases such as asthma, in which leukotrienes mediate inflammation. The aim of this study is to assess the effect of zileuton controlled-release (CR; 1200 mg 2-times daily \[BID\]) on pulmonary function, asthma control, and symptomatic response in adult patients with asthma poorly controlled on moderate dose ICS.

Conditions

  • Asthma

Interventions

  • Zileuton CRDrug

    Zileuton CR tablets 2x600mg BID for 24 weeks

  • PlaceboDrug

    Placebo tablets 2x600mg BID for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pulmonary function measuresTime frame: 3 and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Critical Therapeutics

    Lexington, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.